Gastric cancer and the epoch of immunotherapy approaches

World Journal of Gastroenterology

Volumn 21, Issue 19, 2015, Pages 5778-5793

  Niccolai, Elena ^a   Taddei, Antonio ^b,c   Prisco, Domenico ^a,c   Amedei, Amedeo ^a,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Dendritic cells; Gastric cancer; Immunotherapy; Monoclonal antibodies; NK cells; T cells

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; PANITUMUMAB; RILOTUMUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOPTIVE TRANSFER; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; HUMAN; METASTASIS; MOLECULAR BIOLOGY; NATURAL KILLER T CELL; OVERALL SURVIVAL; PALLIATIVE THERAPY; PERIOPERATIVE PERIOD; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); STOMACH CANCER; SURVIVAL RATE; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; STOMACH NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929630606     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i19.5778     Document Type: Article

References (150)

1. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005;366:1784-1793 [PMID: 16298215 DOI: 10.1016/S0140-6736 (05) 67725-2]
2. Catalano V, Labianca R, Beretta GD, Gatta G, De Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2009;71:127-164 [PMID: 19230702 DOI: 10.1016/j.critrevonc.2009.01.004]
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49 [PMID: 14320675]
4. Haenszel W, Kurihara M, Segi M, Lee RK. Stomach cancer among Japanese in Hawaii. J Natl Cancer Inst 1972;49:969-988 [PMID: 4678140]
5. Terry P, Nyrén O, Yuen J. Protective effect of fruits and vegetables on stomach cancer in a cohort of Swedish twins. Int J Cancer 1998;76:35-37 [PMID: 9533759]
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
7. Schuhmacher C, Reim D, Novotny A. Neoadjuvant treatment for gastric cancer. J Gastric Cancer 2013;13:73-78 [PMID: 23844320 DOI: 10.5230/jgc.2013]
8. Van Hagen P, Hulshof MC, Van Lanschot JJ, Steyerberg EW, Van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, Ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, Van Dekken H, Van Der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, Van Rij CM, Reinders JG, Tilanus HW, Van Der Gaast A. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-2084 [PMID: 22646630 DOI: 10.1056/NEJMoa1112088]
9. Kofoed SC, Muhic A, Baeksgaard L, Jendresen M, Gustafsen J, Holm J, Bardram L, Brandt B, Brenø J, Svendsen LB. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg 2012;101:26-31 [PMID: 22414465 DOI: 10.1177/145749691210 100106]
10. Oh DY, Bang YJ. Adjuvant and neoadjuvant therapy for gastric cancer. Curr Treat Options Oncol 2013;14:311-320 [PMID: 23686725 DOI: 10.1007/s11864-013-0238-4]
11. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45:931-991 [PMID: 19171476 DOI: 10.1016/j.ejca.2008.11.018]
12. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; (3): CD004064 [PMID: 20238327 DOI: 10.1002/14651858. CD004064.pub3]
13. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997 [PMID: 17075117 DOI: 10.1200/JCO.2006.06.8429]
14. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46 [PMID: 18172173 DOI: 10.1056/NEJMoa073149]
15. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529-1534 [PMID: 19474114 DOI: 10.1093/annonc/mdp047]
16. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-2252 [PMID: 14657432 DOI: 10.1056/NEJMra035010]
17. Elkord E, Hawkins RE, Stern PL. Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opin Biol Ther 2008;8:385-395 [PMID: 18352844 DOI: 10.1517/14712598.8.4.385]
18. Niccolai E, Prisco D, D'Elios MM, Amedei A. What is recent in pancreatic cancer immunotherapy? Biomed Res Int 2013;492372 [DOI: 10.1155/2013/492372]
19. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676 [PMID: 12778165 DOI: 10.1038/nm0603-669]
20. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307 [PMID: 16557261 DOI: 10.1038/nri1806]
21. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-478 [PMID: 3052279 DOI: 10.1146/annurev. bi.57.070188.002303]
22. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, Nagura H. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74:795-804 [PMID: 8039107]
23. Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996;2:909-914 [PMID: 9816249]
24. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N, Volant A. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005;93:107-115 [PMID: 15986037 DOI: 10.1038/sj.bjc.6602625]
25. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, Geradts J, Javle M, Brattain M. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004;8:448-453 [PMID: 15120370 DOI: 10.1016/j.gassur.2004.01.006]
26. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096 [PMID: 19188670 DOI: 10.1200/JCO.2009.21.9170]
27. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]
28. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]
29. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-1619 [PMID: 16575012 DOI: 10.1200/JCO.2005.03.4900]
30. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-1318 [PMID: 9815926]
31. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-1333 [PMID: 8340945 DOI: 10.1093/jnci/85.16.1327]
32. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007;120:781-787 [PMID: 17096332 DOI: 10.1002/ijc.22370]
33. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-727 [PMID: 16929325 DOI: 10.1038/nrc1913]
34. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]
35. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664 [PMID: 17470858 DOI: 10.1200/JCO.2006.08.1620]
36. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004;58:984-990 [PMID: 14967460 DOI: 10.1016/j.ijrobp. 2003.09.098]
37. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22:175-184 [PMID: 14701780 DOI: 10.1200/JCO.2004.05.114]
38. Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008;99:868-874 [PMID: 19238629 DOI: 10.1038/sj.bjc.6604622]
39. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510-517 [PMID: 17164226 DOI: 10.1093/annonc/mdl459]
40. Enzinger PC, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson AB, Mayer RJ, Goldberg RM. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010;28 Suppl 15:4006
41. Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, Saffery C, Chua YJ, Chau I. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 2010;28:3945-3950 [PMID: 20679619 DOI: 10.1200/JCO.2010.29.2847]
42. Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, Plette A, Evans D, Wanebo H, Akerman P, Spector J, Kennedy N, Kennedy T. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008;70:391-395 [PMID: 17980508 DOI: 10.1016/j.ijrobp. 2007.07.2325]
43. Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, Von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011;29:626-631 [PMID: 21205757 DOI: 10.1200/JCO.2010.31.9715]
44. Kleinberg LR, Catalano PJ, Gibson MK, Staley CA, Montgomery EA, Song W, Mulcahy MF, Leichman LP, Benson AB. ECOG 2205: A phase II study to measure response rate and toxicity of neo-adjuvant chemoradiotherapy (CRT) (IMRT permitted) with oxaliplatin and infusional 5-fluorouracil plus cetuximab in patients with operable adenocarcinoma of the esophagus: High risk of postop adult respiratory distress syndrome. Int J Radiat Oncol Biol Phys 2011;78:S72 [DOI: 10.1016/j.ijrobp. 2010.07.201]
45. Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 2011;11:466 [PMID: 22035459 DOI: 10.1186/1471-2407-11-466]
46. Casalini P, Iorio MV, Galmozzi E, Ménard S. Role of HER receptors family in development and differentiation. J Cell Physiol 2004;200:343-350 [PMID: 15254961 DOI: 10.1002/jcp. 20007]
47. Al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993;54:213-219 [PMID: 8098013 DOI: 10.1002/ijc.2910540209]
48. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-568 [PMID: 11458821 DOI: 10.1081/CNV-100103852]
49. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neu gene amplification by FISH predicts poor survival in Barrett' s esophagus-associated adenocarcinoma. Hum Pathol 2000;31:35-39 [PMID: 10665910 DOI: 10.1016/S0046-8177 (00) 80195-1]
50. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51 [PMID: 17611206 DOI: 10.1056/NEJMra043186]
51. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672 [PMID: 16236737 DOI: 10.1056/NEJMoa052306]
52. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684 [PMID: 16236738 DOI: 10.1056/NEJMoa052122]
53. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36 [PMID: 17208639 DOI: 10.1016/S0140-6736 (07) 60028-2]
54. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648 [PMID: 10561337]
55. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726 [PMID: 11821453 DOI: 10.1200/JCO.20.3.719]
56. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792 [PMID: 11248153 DOI: 10.1056/NEJM200103153441101]
57. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736 (10) 61121-X]
58. Safran H, Dipetrillo T, Akerman P, Ng T, Evans D, Steinhoff M, Benton D, Purviance J, Goldstein L, Tantravahi U, Kennedy T. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67:405-409 [PMID: 17097832 DOI: 10.1016/j.ijrobp. 2006.08.076]
59. Pegram MD, Blackwell K, Miles D, Bianchi GV, Krop IE, Welslau M, Baselga J, Oh D, Dieras V, Guardino E, Olsen SR, Fang L, Lu M, Verma S. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. J Clin Oncol 2012;30 suppl 27: abstract 98
60. Hong TS, Wo JY, Kwak EL. Ta rge t ed the r api e s wi th chemoradiation in esophageal cancer: development and future directions. Semin Radiat Oncol 2013;23:31-37 [PMID: 23207045 DOI: 10.1016/j.semradonc.2012.09.004]
61. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-3139 [PMID: 17098419 DOI: 10.1016/j.ejca.2006.09.015]
62. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25 [PMID: 9034784 DOI: 10.1210/er.18.1.4]
63. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997;79:206-213 [PMID: 9010092]
64. Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M, Kuwabara M, Yoshida K, Hirai T, Kajiyama G, Tahara E. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998;4:2195-2200 [PMID: 9748139]
65. Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87:95-104 [PMID: 15282704 DOI: 10.1002/jso.20070]
66. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6:1161-1168 [PMID: 10741747]
67. Imdahl A, Bognar G, Schulte-Mönting J, Schöffel U, Farthmann EH, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002;21:657-663 [PMID: 11932164 DOI: 10.1016/S1010-7940 (02) 00044-1]
68. Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, Hayashi H, Takeda A, Shiratori T, Uno T, Ito H, Ochiai T. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002;86:552-557 [PMID: 11870536 DOI: 10.1038/sj.bjc.6600129]
69. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-863 [PMID: 8608475]
70. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000;153:7-12 [PMID: 10779624 DOI: 10.1016/S0304-3835 (99) 00426-7]
71. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
72. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550 [PMID: 17167137 DOI: 10.1056/NEJMoa061884]
73. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676 [PMID: 18160686 DOI: 10.1056/NEJMoa072113]
74. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989 [PMID: 11533692 DOI: 10.1038/nm0901-987]
75. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147 [PMID: 14745444 DOI: 10.1038/nm988]
76. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206 [PMID: 17114652 DOI: 10.1200/JCO.2006.08.0887]
77. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29:868-874 [PMID: 21189380 DOI: 10.1200/JCO.2010.32.0770]
78. Enzinger PC, Ryan DP, Regan E, Lehman N, Abrams TA, Hezel AF, Fidias P, Sequist LV, Blaszkowsky LS, Fuchs CS. Phase II trial of docetaxel, cisplatin, irinotecan and bevacizumab in patients with metastatic esophagogastric cancer (abstract 97). San Francisco, CA: Gastrointestinal Cancers Symposium, 2008: Jan 25
79. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976 [PMID: 21844504 DOI: 10.1200/JCO.2011.36.2236]
80. Willett CG, Boucher Y, Duda DG, Di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-8139 [PMID: 16258121 DOI: 10.1200/JCO.2005.02.5635]
81. Bendell JC, Meluch A, Peyton J, Rubin M, Waterhouse D, Webb C, Burris HA, Hainsworth JD. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol 2012;10:430-437 [PMID: 22895283]
82. Ilson D, Goodman KA, Janjiigian YY, Shah MA, Kelsen DP, Rizk NP, Rusch VW, Wu AJ, Campbell J, Capanu M, Bains MS, Memorial Sloan-Kettering Cancer Center, New York, NY, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma. J Clin Oncol 2012;20 suppl 4: abstract 67
83. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-848 [PMID: 21102609 DOI: 10.1038/nrm3012]
84. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-2214 [PMID: 19318488 DOI: 10.1158/1078-0432. CCR-08-1306]
85. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925 [PMID: 14685170 DOI: 10.1038/nrm1261]
86. Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001;158:1111-1120 [PMID: 11238059 DOI: 10.1016/S0002-9440 (10) 64058-8]
87. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;103:2316-2321 [PMID: 16461907 DOI: 10.1073/pnas.0508776103]
88. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043 [PMID: 17463250 DOI: 10.1126/science.1141478]
89. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88 [PMID: 20129249 DOI: 10.1016/j.ccr.2009.11.022]
90. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, Iafrate AJ. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a nonsmall cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-946 [PMID: 21623265 DOI: 10.1097/JTO.0b013e31821528d3]
91. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47:1025-1037 [PMID: 18709663 DOI: 10.1002/gcc.20604]
92. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 2007;97:368-377 [PMID: 17667909 DOI: 10.1038/sj.bjc.6603884]
93. Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, Donehower RC, Jiang Y, Dubey S, Loh E, Amgen Inc., Thousand Oaks, CA; Southampton General Hospital, Southampton, United Kingdom; Johns Hopkins Cancer Center, Baltimore, MD; Amgen Inc., South San Francisco, CA Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients with locally advanced or metastatic gastric or esophagogastric junction cancer. J Clin Oncol 2012;30:4005
94. Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis 2002;39:E5 [PMID: 11774131 DOI: 10.1053/ajkd.2002.29926]
95. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964 [PMID: 17008531 DOI: 10.1126/science.1129139]
96. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854 [PMID: 12242449 DOI: 10.1126/science.1076514]
97. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4 (+) CD25 (+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772 [PMID: 11406550]
98. Kim JH, Kang TH, Noh KH, Kim SH, Lee YH, Kim KW, Bae HC, Ahn YH, Choi EY, Kim JS, Lee KM, Kim TW. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN. Immunol Lett 2010;134:47-54 [PMID: 20727912 DOI: 10.1016/j.imlet.2010.08.008]
99. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117:1204-1212 [PMID: 17476350 DOI: 10.1172/JCI31446]
100. Eberts D, Fatho M, Lennerz V, Schmidt C, Van Der Bruggen P, Woelfel C, Woelfel T, Melanoma-associated Mhc Class I associated oligopeptides and the uses thereof. WO/2007/025760, 2007
101. Argonex Pharmaceuticals. Cytotoxic T Lymphocyte-stimulation peptides for prevention, treatment, and diagnosis of melanoma. WO/2001/032193, 2001
102. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168-16173 [PMID: 12427970 DOI: 10.1073/pnas.242600099]
103. Gang Y, Zhang X, He Y, Zheng J, Wu K, Ding J, Fan D. Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide. Biochem Cell Biol 2012;90:701-708 [PMID: 22992138 DOI: 10.1139/o2012-028]
104. ∗2402-restricted CTL epitopepeptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response. Oncol Rep 2011;25:469-476 [PMID: 21165574]
105. Kim YJ, Lim J, Kang JS, Kim HM, Lee HK, Ryu HS, Kim JY, Hong JT, Kim Y, Han SB. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res 2010;33:1789-1795 [PMID: 21116782 DOI: 10.1007/s12272-010-1111-7]
106. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011;2:363-368 [PMID: 21716717 DOI: 10.7150/jca.2.363]
107. Hoshino T, Seki N, Kikuchi M, Kuramoto T, Iwamoto O, Kodama I, Koufuji K, Takeda J, Itoh K. HLA class-I-restricted and tumorspecific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 1997;70:631-638 [PMID: 9096641]
108. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998;78:202-208 [PMID: 9754653]
109. Guo DL, Dong M, Wang L, Sun LP, Yuan Y. Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori-associated gastric diseases. World J Gastroenterol 2002;8:1009-1013 [PMID: 12439915]
110. Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D. Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol 2009;24:37-41 [PMID: 19196394 DOI: 10.1111/j.1440-1746.2008.05753.x]
111. Nie Y, Wu K, Yang J, Tian F, Li L, Chen B, Fan D. Induction of T lymphocytes specific to human gastric cancer using HLA-A matched allogeneic gastric tumor cells. J Immunother 2003;26:403-411 [PMID: 12973029 DOI: 10.1097/00002371-200309000-00003]
112. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, Nilsson-Ehle P. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 2006;26:2237-2242 [PMID: 16821594]
113. Wu C, Jiang J, Shi L, Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008;28:3997-4002 [PMID: 19192663]
114. Du X, Jin R, Ning N, Li L, Wang Q, Liang W, Liu J, Xu Y. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Oncol Rep 2012;28:1743-1749 [PMID: 22948809]
115. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332-342 [PMID: 12843795 DOI: 10.1097/00002371-200 307000-00005]
116. Alexander RB, Rosenberg SA. Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunol 1990;145:1615-1620 [PMID: 1974569]
117. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 2002;8:1767-1771 [PMID: 12060615]
118. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-1166 [PMID: 8028037 DOI: 10.1093/jnci/86.15.1159]
119. Tomsová M, Melichar B, Sedláková I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008;108:415-420 [PMID: 18037158 DOI: 10.1016/j.ygyno. 2007.10.016]
120. Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, Bechi P, Taddei A, Bencini L, Farsi M, Cappello P, Prisco D, Novelli F, D'Elios MM. Ex vivo analysis of pancreatic cancerinfiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother 2013;62:1249-1260 [PMID: 23640603 DOI: 10.1007/s00262-013-1429-3]
121. Amedei A, Niccolai E, Della Bella C, Cianchi F, Trallori G, Benagiano M, Bencini L, Bernini M, Farsi M, Moretti R, Del Prete G, D'Elios MM. Characterization of tumor antigen peptidespecific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma. Cancer Immunol Immunother 2009;58:1819-1830 [PMID: 19319530 DOI: 10.1007/s00262-009-0693-8]
122. Amedei A, Munari F, Bella CD, Niccolai E, Benagiano M, Bencini L, Cianchi F, Farsi M, Emmi G, Zanotti G, De Bernard M, Kundu M, D'Elios MM. Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. Intern Emerg Med 2014;9:303-309 [PMID: 23054412 DOI: 10.1007/s11739-012-0867-9]
123. Shen Z, Zhou S, Wang Y, Li RL, Zhong C, Liang C, Sun Y. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol 2010;136:1585-1595 [PMID: 20221835 DOI: 10.1007/s00432-010-0816-9]
124. Kim HI, Kim H, Cho HW, Kim SY, Song KJ, Hyung WJ, Park CG, Kim CB. The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer. J Surg Oncol 2011;104:728-733 [PMID: 21792941 DOI: 10.1002/jso.22038]
125. Caux C, Ait-Yahia S, Chemin K, De Bouteiller O, Dieu-Nosjean MC, Homey B, Massacrier C, Vanbervliet B, Zlotnik A, Vicari A. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 2000;22:345-369 [PMID: 11155441 DOI: 10.1007/s002810000053]
126. Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-480 [PMID: 15122249 DOI: 10.1038/nm1039]
127. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific CTLmediated protective tumor immunity. J Exp Med 1996;183:283-287 [PMID: 8551233 DOI: 10.1084/jem.183.1.283]
128. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117:1195-1203 [PMID: 17476349 DOI: 10.1172/JCI31205]
129. Ishigami S, Natsugoe S, Uenosono Y, Hata Y, Nakajo A, Miyazono F, Matsumoto M, Hokita S, Aikou T. Infiltration of antitumor immunocytes into the sentinel node in gastric cancer. J Gastrointest Surg 2003;7:735-739 [PMID: 13129549]
130. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, Aridome K, Hokita S, Aikou T. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000;159:103-108 [PMID: 10974412 DOI: 10.1016/S0304-3835 (00) 00542-5]
131. Tsujitani S, Kakeji Y, Orita H, Watanabe A, Kohnoe S, Baba H, Anai H, Maehara Y, Sugimachi K. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Anticancer Res 1992;12:645-648 [PMID: 1622120]
132. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002;8:3394-3400 [PMID: 12429626]
133. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001;7:2277-2284 [PMID: 11489802]
134. Available from: URL: http://www.clinicaltrials.gov
135. Galetto A, Contarini M, Sapino A, Cassoni P, Consalvo E, Forno S, Pezzi C, Barnaba V, Mussa A, Matera L. Ex vivo host response to gastrointestinal cancer cells presented by autologous dendritic cells. J Surg Res 2001;100:32-38 [PMID: 11516202 DOI: 10.1006/jsre.2001.6158]
136. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, Kumar S, Wu TC. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003;112:109-117 [PMID: 12840065 DOI: 10.1172/JCI17293]
137. Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 2008;27:5464-5476 [PMID: 18794881 DOI: 10.1038/onc.2008.243]
138. Kim JH, Kang TH, Noh KH, Bae HC, Ahn YH, Lee YH, Choi EY, Chun KH, Lee SJ, Kim TW. Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. Clin Exp Immunol 2011;165:180-189 [PMID: 21592111 DOI: 10.1111/j.1365-2249.2011.04410.x]
139. He SB, Sun K, Wang L, Li DC, Zhang YY. [GM-CSF genemodified dendritic cell vaccine enhances antitumor immunity in vitro]. Zhonghua Zhongliu Zazhi 2010;32:410-414 [PMID: 20819479]
140. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-3633 [PMID: 16308572 DOI: 10.1172/JCI25947]
141. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer celldeficient mice. Proc Natl Acad Sci USA 2000;97:2731-2736 [PMID: 10694580 DOI: 10.1073/pnas.050588297]
142. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79:2320-2328 [PMID: 9191519]
143. Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol 2006;118:1-10 [PMID: 16337194 DOI: 10.1016/j.clim.2005.10.011]
144. Rosso D, Rigueiro MP, Kassab P, Ilias EJ, Castro OA, Novo NF, Lourenço LG. [Correlation of natural killer cells with the prognosis of gastric adenocarcinoma]. Arq Bras Cir Dig 2012;25:114-117 [PMID: 23381755]
145. Saito H, Takaya S, Osaki T, Ikeguchi M. Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients. Gastric Cancer 2013;16:473-479 [PMID: 23179366 DOI: 10.1007/s10120-012-0210-1]
146. Voskens CJ, Watanabe R, Rollins S, Campana D, Hasumi K, Mann DL. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res 2010;29:134 [PMID: 20937115 DOI: 10.1186/1756-9966-29-134]
147. Wu XT, Liu JQ, Lu XT, Chen FX, Zhou ZH, Wang T, Zhu SP, Fei SJ. The enhanced effect of lupeol on the destruction of gastric cancer cells by NK cells. Int Immunopharmacol 2013;16:332-340 [PMID: 23639256 DOI: 10.1016/j.intimp. 2013.04.017]
148. Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol 2014;20:1657-1666 [PMID: 24587645 DOI: 10.3748/wjg.v20.i7.1657]
149. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526 [PMID: 21639810 DOI: 10.1056/NEJMoa1104621]
150. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-2047 [PMID: 22271879 DOI: 10.1158/1078-0432. CCR-11-1823]